VIVUS shares should be bought on any weakness, says JMP Securities After CHMP recommended against the approval of VIVUs' Qsiva drug in Europe, JMP Securities thinks the news was expected and had already been reflected in the stock. The firm reiterates an Outperform rating on the shares.
News For VVUS From The Last 14 Days
Check below for free stories on VVUS the last two weeks.
On The Fly: Analyst Downgrade Summary Today's noteworthy downgrades include: AVG Technologies (AVG) downgraded to Neutral from Buy at Goldman... Cigna (CI) downgraded to Hold from Buy at Jefferies... Cree (CREE) downgraded to Neutral from Buy at Sterne Agee... Melco Crown (MPEL) downgraded to Neutral from Buy at UBS... SolarCity (SCTY) downgraded to Neutral from Buy at Roth Capital... KB Home (KBH) downgraded to Market Perform from Outperform at Raymond James... Ryland Group (RYL) downgraded to Underperform from Market Perform at Raymond James... Alere (ALR) downgraded to Hold from Buy at Craig-Hallum... Evolution Petroleum (EPM) downgraded to Hold from Buy at MLV Equity... Oil States (OIS) downgraded to Hold from Buy at BB&T... VIVUS (VVUS) downgraded to Neutral from Buy at Lazard Capital.
Subscribe for More Information
